The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Differences in outcome due to bevacizumab (BEV) discontinuation versus BEV failure in adults with glioblastoma.
Mark Daniel Anderson
No relevant relationships to disclose
Vinay K. Puduvalli
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Bayer; Celgene; Genentech; Merck
Mohamed Ali Hamza
No relevant relationships to disclose
Mark R. Gilbert
Consultant or Advisory Role - Abbott Laboratories; Genentech; Merck
Honoraria - Genentech; Merck
Research Funding - Genentech; Merck
W. K. Alfred Yung
Consultant or Advisory Role - Actelion; Merck
Honoraria - Actelion; Merck; Novartis
Research Funding - Daiichi Sankyo; Novartis